Focusing on glaucoma progression and the clinical importance of progression rate measurement: a review.

作者: L Rossetti , F Goni , P Denis , B Bengtsson , A Martinez

DOI: 10.1038/EYE.2010.112

关键词:

摘要: PURPOSE: This review aims to provide guidance in managing glaucoma patients more effectively. It focuses on the importance of detecting progression and measuring its rate within management primary open-angle today. Recent findings strongly indicate that continued monitoring visual fields (VFs) reassessment target intraocular pressures (IOPs) depending VF rates are mandatory glaucoma. METHODS: Data from older as well most recent literature summarized this article. In addition, article elaborates scientific content a series lectures given by experts field during several international symposia 'rate progression' 2008. RESULTS: summarizes key natural history known factors for disease progression. highlights function changes observed progresses discusses impact patients' quality life. Findings support need obtain information clinical management. Practical ways measure new software options help major parameters. Finally, basis patient's individual therapeutic assessed, such maximum medical therapy with fixed combinations. CONCLUSIONS: Estimating using newly developed analyses will be helpful forecast potential future development An individualized treatment approach then requires whom risk becoming visually impaired or blind their lifetime is higher, intensive IOP-lowering combinations can considered option. (Less)

参考文章(30)
Tim Mills, Simon K. Law, John Walt, Patricia Buchholz, Jan Hansen, Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs & Aging. ,vol. 26, pp. 933- 950 ,(2009) , 10.2165/11316830-000000000-00000
Natural history of normal-tension glaucoma. Ophthalmology. ,vol. 108, pp. 247- 253 ,(2001) , 10.1016/S0161-6420(00)00518-2
Gisela Kobelt, Björn Jonsson, Anders Bergström, Enping Chen, Christina Lindén, Albert Alm, Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden Acta Ophthalmologica Scandinavica. ,vol. 84, pp. 363- 371 ,(2006) , 10.1111/J.1600-0420.2005.00621.X
Jessica E. Oliver, Matthew G. Hattenhauer, David Herman, David O. Hodge, Robert Kennedy, Michael Fang-Yen, Douglas H. Johnson, Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. American Journal of Ophthalmology. ,vol. 133, pp. 764- 772 ,(2002) , 10.1016/S0002-9394(02)01403-4
J H Gurwitz, R J Glynn, M Monane, D E Everitt, D Gilden, N Smith, J Avorn, Treatment for glaucoma: adherence by the elderly. American Journal of Public Health. ,vol. 83, pp. 711- 716 ,(1993) , 10.2105/AJPH.83.5.711
Howard S. Barnebey, Silvia Orengo-Nania, Brian E. Flowers, John Samples, Sushanta Mallick, Theresa A. Landry, Michael V.W. Bergamini, The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. American Journal of Ophthalmology. ,vol. 140, pp. 1- 7 ,(2005) , 10.1016/J.AJO.2005.02.043
Aachal Kotecha, Neil O'Leary, Dean Melmoth, Simon Grant, David P. Crabb, The Functional Consequences of Glaucoma for Eye-Hand Coordination Investigative Ophthalmology & Visual Science. ,vol. 50, pp. 203- 213 ,(2009) , 10.1167/IOVS.08-2496
Balwantray C. Chauhan, Canadian Glaucoma Study Archives of Ophthalmology. ,vol. 126, pp. 1030- 1036 ,(2008) , 10.1001/ARCHOPHT.126.8.1030
Luca Rossetti, Costas H Karabatsas, Fotis Topouzis, Michele Vetrugno, Marco Centofanti, Andreas Boehm, Ananth Viswanathan, Christian Vorwerk, David Goldblum, None, Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology. ,vol. 114, pp. 2244- 2251 ,(2007) , 10.1016/J.OPHTHA.2007.01.025